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Genome-wide association study of white-coat effect in hypertensive patients 
Background: White-coat effect (WCE) confounds diagnosis and treatment of hypertension. 
The prevalence of white-coat hypertension is higher in Europe and Asia compared to other 
continents suggesting that genetic factors could play a role. 
Methods: To study genetic variation affecting WCE, we conducted a two-stage genome-wide 
association study involving 1343 Finnish subjects. For the discovery stage, we used Genetics 
of Drug Responsiveness in Essential Hypertension (GENRES) cohort (n = 206), providing the 
mean WCE values from up to four separate office/ambulatory recordings conducted on 
placebo. Associations with p values < 1 × 10-5 were included in the replication step in three 
independent cohorts: Haemodynamics in Primary and Secondary Hypertension (DYNAMIC) 
(n = 182), Finn-Home study (n = 773) and Dietary, Lifestyle and Genetic Determinants of 
Obesity and Metabolic Syndrome (DILGOM) (n =182). 
Results: No single nucleotide polymorphisms reached genome-wide significance for 
association with either systolic or diastolic WCE. However, two loci provided suggestive 
evidence for association. A known coronary artery disease risk locus rs2292954 in SPG7 
associated with systolic WCE (discovery p value = 2.2 × 10-6 , replication p value = 0.03 in 
Finn-Home, meta-analysis p value 2.6 × 10-4), and rs10033652 in RASGEF1B with diastolic 
WCE (discovery p value = 4.9 × 10-6, replication p value = 0.04 in DILGOM, meta-analysis p 
value = 5.0 × 10-3). 
Conclusion: This study provides evidence for two novel candidate genes, SPG7 and 
RASGEF1B, associating with WCE. Our results need to be validated in even larger studies 
carried out in other populations.  
Keywords: white-coat effect, hypertension, gene, genome-wide, SPG7, RASGEF1B 
Introduction 
A proper diagnosis and rational treatment of hypertension, the leading risk factor for cardiovascular 
disease, is confounded by the white-coat effect (WCE), implying that blood pressure (BP) measured 
by healthcare personnel at the office (OBP) is usually higher than BP measured using ambulatory 
BP (ABP) monitoring or by the patients themselves at home [1,2]. WCE is perceived as a pressor 
response driven by an anxious reaction to BP measurement [3]. It is a common phenomenon that 
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becomes more pronounced at higher BP levels [4]. The main problem caused by WCE is white-coat 
hypertension, identified by elevated OBP, but normal ABP or home BP [1]. At present, the 
consensus is that white-coat hypertension and accentuated WCE carry little cardiovascular risk 
compared to true normotension [5], but there is a growing body of contradictory reports of 
association with target organ damage [6], cardiovascular events [7] and increased cardiovascular 
mortality [8]. 
Despite the obvious problems it causes for clinicians in decision of using antihypertensive 
treatment, the mechanisms underlying WCE are not well understood. However, many correlates for 
WCE have been identified. A recent meta-analysis of existing literature (70 studies, 86,167 patients) 
identified sex, body mass index (BMI), smoking status and systolic BP (SBP) level as the most 
important predictors of WCE [9]. Interestingly, the ARTEMIS Study, an international multicenter 
study involving 14,143 patients from 27 countries, reported higher prevalence of white-coat 
hypertension in Europe and Asia compared to Australia, America and Africa, suggesting that 
genetic factors could partly explain WCE [10]. Apart from a few candidate gene studies, the genetic 
background of WCE has not been extensively studied. Recently, a Japanese group conducted a 
genome-wide association study (GWAS) of WCE, using a discovery study with 295 and replication 
study with 236 individuals, but no significant associations were discovered [11], possibly due to 
only moderate reproducibility of WCE [12]. Thus, even larger studies of WCE genetics are 
required, also to provide new insights for genetics of BP regulation [13]. In addition, identifying 
genetic loci associated with WCE would provide a tool to investigate the causal relationship 
between white coat hypertension and cardiovascular target organ damage through Mendelian 
randomization. 
To study possible genetic influence on WCE, we conducted a GWAS of WCE in the Finnish 
Genetics of Drug Responsiveness in Essential Hypertension (GENRES) cohort (n =206) [14,15]. As 
GENRES includes repeated measurements of OBP and ABP under placebo treatment, it provides a 
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unique opportunity to reduce intraindividual variability of WCE. Replication analyses were 
conducted in three other Finnish cohorts: Hemodynamics in Primary and Secondary Hypertension 
(DYNAMIC) (n = 182) [16,17], the Finn-Home study (n = 773) [5,18] and Dietary, Lifestyle and 
Genetic Determinants of Obesity and Metabolic Syndrome (DILGOM) (n = 182) [19]. 
Methods 
Overview of participating studies 
Four Finnish study cohorts (combined n = 1343) were included in this study: GENRES, 
DYNAMIC, Finn-Home and DILGOM. 
GENRES cohort originates from a randomized, double-blind, cross-over, placebo-controlled 
study on pharmacogenomics of drug responsiveness in essential hypertension. The clinical phase 
was conducted between 1999 and 2004 in Helsinki University Hospital (clinicaltrials.gov 
NCT03276598). The study design and rationale have been previously published elsewhere [14,15]. 
In brief, the subjects were moderately hypertensive Finnish men (aged 35 to 60 years) who went 
through four one-month drug treatment periods (losartan 50 mg, amlodipine 5 mg, 
hydrochlorothiazide 25 mg and bisoprolol 5 mg once a day) in randomized order, separated by one-
month placebo periods. OBP and 24-hour ABP measurements were carried out at the end of each 
period (Supplementary Figure 1). The inclusion of intervening placebo periods in the study design 
provides a unique opportunity to study WCE as a mean of up to four separate measurements 
conducted at two-month intervals. Thus, GENRES cohort was used for the discovery GWAS. To 
further reduce within-subject variability, only the 206 unrelated subjects with ≥ 3 placebo WCE 
measurements and genotyping data available were included in the present study. Each subject gave 
written informed consent and the study was approved by the Ethics Committee of Helsinki 
University Central Hospital and National Agency of Medicines of Finland. 
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DYNAMIC (clinicaltrials.gov NCT01742702) is an ongoing study to investigate 
hemodynamic changes in primary and secondary hypertension with a non-invasive hemodynamic 
measurement protocol [16,17]. A total of 187 subjects with WCE assessment available were 
genotyped. One subject was excluded due to low success rates (>95 %) of genotyping, one subject 
was excluded due to morbid obesity (BMI > 40) and three subjects were excluded due to first 
degree relativeness; ultimately, 182 unrelated subjects were included in the present replication 
study. Each subject gave written informed consent and the study was approved by the Ethics 
Committee of Tampere University Hospital. 
Finn-Home cohort originates from a multidisciplinary epidemiological survey, the Health 
2000 Survey, carried out in Finland from 2000 to 2001, from which individuals aged 45-74 years 
with home BP monitors available were recruited to the study [5,18]. This population sample 
underwent office and home BP measurements and risk factor evaluation to investigate the 
prognostic significance of home BP. A total of 786 subjects had BP and genotype data available. 
Twelve subjects were excluded due to morbid obesity (BMI > 40) and one subject due to WCE 
residual differing more than four standard deviations from mean, resulting in 773 unrelated subjects 
to be included in the present replication study. The study protocol of the Health 2000 survey was 
approved by Epidemiology Ethics Committee of Helsinki and Uusimaa Hospital region and all 
participants gave written informed consent. 
The DILGOM (Dietary, Lifestyle and Genetic determinants of Obesity and Metabolic 
syndrome) was a population survey conducted in 2007 to assess the effects of environmental and 
genetic factors on obesity and metabolic syndrome. Four hundred and ninety-four subjects from 
Southwestern Finland participated in a cardiovascular substudy. In 2014 the still living participants 
of the cardiovascular substudy were invited to a study comparing traditional and novel BP 
measurements [19]. Both WCE and genetic data were available for 209 subjects. Four morbidly 
obese (BMI > 40) subjects and 23 subjects over the age of 75 were excluded resulting in 182 
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unrelated subjects to be included in the present replication cohort. Each subject gave written 
informed consent and the study was approved by the Ethics Committee of the Hospital District of 
Southwest Finland. 
BP measurement in participating studies 
In GENRES OBP was measured after a 30-minute rest using a semi-automated oscillometric device 
(Omron M4; Omron Healthcare, Tokyo, Japan) by a study nurse. Three measurements were taken 
and the mean of the last two was used for the analyses. 24-hour ABP measurement was conducted 
with a device equipped with a position sensor (Diasys Integra; Novacor, Rueil-Malmaison, France). 
Readings were taken every 15 minutes when standing and every 30 minutes when supine. Intense 
physical activity was not permitted. Daytime was defined as hours between 7 am and 10 pm. Single 
observations were excluded from the analysis due to low pulse pressure (<15 mmHg if SBP <120 
and <20 mmHg if SBP > 120), high heart rates ≥ 110, lying down during daytime or high physical 
activity. For a recording to be accepted for this study, > 15 daytime measurements were required. 
In DYNAMIC OBP was measured by a physician after at least 10 minutes of rest in the 
seated position using a calibrated aneroid sphygmomanometer (Heine Gamma G7, HEINE 
Optotechnik, Herrsching, Germany). The phase I and V Korotkoff sounds were used to identify 
systolic and diastolic BP, respectively. Two measurements at about 2-minute intervals were taken 
and the mean of these values was used for the analyses. If either systolic or diastolic readings 
differed by more than 10 mmHg, a third measurement was taken and the mean value of the last two 
measurements was used for the analyses. Heart rate was recorded by pulse palpation after the last 
measurement in the sitting position. Microlife WatchBP O3 monitor (Microlife AG, Widnau, 
Switzerland) was used to measure 24-hour ABP. Readings were taken every 20 minutes during the 
day (7 am to 10 pm). Single observations were excluded using the same criteria as described for 
GENRES. 
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In Finn-Home OBP was measured by a trained nurse with a conventional calibrated mercury 
sphygmomanometer. SBP and diastolic BP (DBP) were defined according to Korotkoff sounds I 
and IV. OBP was determined as the mean of two measurements performed at 2-minute interval after 
10-minute rest. Home BP was self-measured with an automatic oscillometric device (Omron model 
HEM-722C, Omron Corporation, Tokyo, Japan). Study participants took duplicate self-
measurements every morning (between 6 am and 9 am) and every evening (between 18 pm and 21 
pm) on seven consecutive days in sitting position with approximately 2-minute interval. Home BP 
was determined as the mean of 14 duplicate measurements (28 measurements). 
In DILGOM OBP was measured twice by a nurse after a 3-minute rest at 1-minute intervals 
with an oscillometric BP monitor (Microlife WatchBP Office Central, Microlife AG, Widnau, 
Switzerland). Twenty-four-hour ABP was then recorded with a Microlife WatchBP O3 monitor 
(Microlife AG, Widnau, Switzerland). Readings were taken every 20 minutes during the day (from 
7 am to 10 pm) and every 30 minutes during the night (from 10 pm to 7 am). Daytime BP was 
defined as the mean of all other BP values except the actual sleeping period at night. 
Genotyping and quality control 
The genotyping methods and quality control steps for GENRES have been described in detail 
before [15]. The DNA samples of the GENRES study subjects were genotyped at the Institute for 
Molecular Medicine Finland (FIMM, Helsinki, Finland) using the Illumina HumanOmniExpress 
BeadChip (Illumina, San Diego, CA, USA). Initial quality control steps included overall genotyping 
success rate (exclusion if < 95 %), identity-by-state clustering and gender check. Of the 709,357 
genotyped autosomal SNPs, 707,658 passed these quality control steps. Afterwards, SNPs with 
genotyping success rate <95 % (759 SNPs), Hardy-Weinberg equilibrium p value < 1 × 10-5 (256 
SNPs) and minor allele frequency < 0.01 (77,231 SNPs) were excluded resulting in 629,414 
genotyped autosomal SNPs available for the analysis. Even though we used only the genotyped 
SNPs for the GWAS, imputed SNPs were used to test candidate SNPs derived from a previous 
8 
 
 
GWAS of WCE (11). For the latter purpose, GENRES genotypes were imputed using IMPUTE2 
[20] and the Hapmap2 CEU release 22 reference panel after pre-phasing with ShapeITv2. Lastly, 
the effect of population stratification on WCE was tested with principal components (PCs) 
generated with program Smartpca from Eigensoft package [21]. A reduced dataset of 114,487 SNPs 
with r2 < 0.5 and the long-range linkage disequilibrium (LD) regions excluded [22] were used. 
Three significant PCs for population stratification with p values <0.10 were identified with program 
Twstats from Eigensoft package, but they were not associated with either systolic or diastolic WCE 
residuals (all p values > 0.20) and accordingly were not included in GWAS analysis. 
The DNA samples of the DYNAMIC study subjects were genotyped at the Institute for 
Molecular Medicine Finland (Helsinki, Finland) using the Illumina HumanOmniExpress BeadChip 
(Illumina, San Diego, CA, USA). One subject was excluded due to low success rate (<95%). The 11 
SNPs used for replication passed the same quality control steps as described for GENRES above. 
The genotype data of the Finn-Home cohort originating from the Health 2000 survey was 
derived from previously conducted GWASs. The DNA samples were genotyped using Illumina 
Infinium HD Human610-Quad BeadChip (Illumina, San Diego, CA, USA). Subsequent imputation 
of SNP genotype data was carried out with MACH 1.0.16 using the HapMap3 CEU and TSI 
populations as an imputation reference. If the selected SNP was not genotyped, the imputed value 
was used. Imputed genotypes were used for SNPs rs9614176, rs10965522, rs2650673 and 
rs10033652. 
The genotype data of the DILGOM study subjects was derived from previously conducted 
GWASs. The DNA samples were genotyped with Illumina Cardio-MetaboChip and Illumina 610K 
arrays (Illumina, San Diego, CA, USA) at the Wellcome Trust Sanger Institute (Cambridge, UK) 
and at the Institute for Molecular Medicine Finland (Helsinki, Finland). Unobserved SNPs were 
imputed using 1000 Genomes haplotypes Phase I integrated variant set release (ShapeITv2) in 
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NCBI build 37 version June 2014. If the selected SNP was not genotyped, the imputed value was 
used. Imputed genotypes were used for SNPs rs10965522, rs2650673 and rs2053425. 
Calculation of white-coat effect residuals for genome-wide association analysis 
WCE was calculated as the difference between OBP and daytime ABP in GENRES, DYNAMIC 
and DILGOM. In the Finn-Home cohort, the WCE was calculated as the difference between OBP 
and home BP. The two WCE traits, systolic WCE and diastolic WCE, were analyzed separately as 
continuous variables using IBM SPSS Statistics 22.0 (IBM Corp., Armonk, NY) and were 
approximately normally distributed. Before genetic association analyses we adjusted both systolic 
and diastolic WCE for significant covariates (p < 0.10 for either systolic or diastolic WCE) using 
linear regression (Supplementary Table 1). The included covariates were age, BMI, corresponding 
daytime ABP and smoking status. Other covariates tested but not included were waist-hip ratio, use 
of antihypertensive drugs before entry to the study, serum creatinine level, urinary excretion of 
sodium after the first placebo period and three PCs (see above). For the replication cohorts that 
included women, sex was included as a covariate as well as the current use of BP medication where 
appropriate. 
Genome-wide association analysis 
Discovery phase 
The discovery GWAS was performed in the GENRES cohort, using covariate-adjusted WCE 
residuals and linear regression under additive genetic model in PLINK v1.07 [23]. The results were 
plotted using Manhattan and quantile-quantile (Q-Q) plots generated with QQman package in R. 
Regional Manhattan plots were generated with Locuszoom package in R. Bonferroni-corrected p 
value < 5 × 10-8 was considered genome-wide significant, and, based on the hypothesis-generating 
nature of the present study, p value < 1 × 10-5 was considered suggestively significant. 
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Replication phase 
Replication analyses in three independent cohorts were carried out for the statistically most 
significant SNPs from each locus with p value < 1 × 10-5. For the replication analyses, covariate-
adjusted WCE residuals were generated using linear regression and same covariates (plus sex) as in 
the discovery GWAS. A Bonferroni-corrected p value < 0.0015 [0.05 / (11 SNPs × 3 studies)] and 
same direction of effect was considered as successful replication, while a p value < 0.05 and same 
direction of effect was considered suggestively significant. We tested for SNP × sex interaction in 
the replication cohorts and conducted a separate analysis in men if it was significant (p < 0.10). We 
also conducted meta-analysis of the top WCE SNPs in all available studies using inverse-variance 
model with fixed effects in METAL (24). We defined significant results as p values < 5×10−8 and p 
values < 1×10−5 were considered to represent a suggestive association. 
Replication of candidate variants from a previous genome-wide association study of white-
coat effect 
We conducted a replication analysis for the associations found in a previous GWAS of WCE [11]. 
SNPs with p values < 5 ×10-5 were chosen for replication, with the exclusion of three SNPs that 
were monoallelic in Finns. Thus, nine SNPs were analyzed for systolic WCE and eight SNPs for 
diastolic WCE. Bonferroni-corrected p value < 0.003 (0.05 / 17 SNPs) with the same direction of 
effect was considered as a significant replication. 
Functional analysis of top associations in silico 
We used Variant Effect Predictor (VEP) to characterize the leading variant from each locus with p 
value < 1 × 10-5 [25,26]. Variants characterized as intergenic SNPs were annotated to the closest 
gene using Ensembl browser version 92 [27,28]. We further conducted an expression quantitative 
trait locus (eQTL) analysis using the Genotype-Tissue Expression (GTEx) Portal [29,30] to identify 
whether the leading variants were cis-eQTLs for nearby genes. 
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As WCE is an anxious reaction to having BP measured [3], we looked if any of the leading 
WCE SNPs had cross-trait associations at a nominal p value < 0.05 with major personality traits 
including neuroticism in three large GWASs with publicly available results: the UK Biobank 
GWAS by Neale lab (n = ~300,000) [31], the Genetics of Personality Consortium (GPC) GWAS (n 
= ~63,000) [32] and the Social Science Genetic Association Consortium (SSGAC) GWAS (n = 
~180,000 – 300,000) [33]. We also looked if the leading WCE SNPs had previously been associated 
at a nominal p value < 0.05 with BP or pulse rate in large BP GWASs with publicly available data: 
the International Consortium of Blood Pressure Genome-Wide Association Studies (ICBP) GWAS 
(n = ~63,000) [34] and UK Biobank GWAS by Neale lab (n = ~300,000) [31]. The GWAS results 
were queried using the Phenoscanner database [35,36] and MR-Base PheWAS database [37,38]. 
Results 
General comparison of the study samples 
The characteristics of the discovery cohort (GENRES) and the replication cohorts (DYNAMIC, the 
Finn-Home study and DILGOM) are summarized in Table 1. The discovery GWAS was carried out 
in GENRES, which consisted of men only, but all replication cohorts consisted of both men and 
women. Thus, a separate replication analysis was performed for men, if sex × SNP interaction was 
significant (p < 0.10). The participants of GENRES and DYNAMIC were all hypertensive, whereas 
the Finn-Home study and DILGOM were population-based studies comprising both normotensive 
and hypertensive individuals. The mean systolic WCE ranged from 1.2 to 8.0 mmHg and the mean 
diastolic WCE from 0.3 to 4.0 mmHg. The standard deviations of the WCEs were the smallest in 
GENRES (Table 1). 
Genome-wide association study of systolic white-coat effect 
The Q-Q plot from the discovery GWAS of systolic WCE showed little evidence of genomic 
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inflation and supported the idea that some of the associations may be significant (Supplementary 
Figure 2A). Manhattan plot of the results (Figure 1A) illustrates four loci with p < 1 × 10-5, but no 
SNPs with genome-wide significance (p < 5 × 10-8) were identified. The four loci with p < 1 × 10-5 
in the discovery GWAS are presented in Table 2, and the local Manhattan plots are depicted in 
Supplementary Figure 3A-D. As the GENRES subjects received four different antihypertensive 
monotherapies in a rotational fashion separated by one-month placebo periods (Supplementary 
Figure 1), it was pertinent to test if the top associations derived from the placebo periods were 
similar when WCE data during administration of the four different drugs were analyzed. The effects 
of the SNPs were consistently in the same direction as during placebo periods and p values for the 
associations often remained statistically significant (Supplementary Table 2). In the GENRES 
study, the WCEs during the drug treatment periods did not differ statistically significantly from 
each other, nor from the mean WCE during placebo periods. 
The most significant association in the discovery GWAS was displayed by rs9614176 on 
chromosome 22 (β = 5.3 mmHg, p = 8.7×10-7) near EFCAB6. In the replication analysis, however, 
we did not find support for this locus. No SNP reached the Bonferroni-corrected p value (0.003) in 
the replication analysis, but rs2292954 (β = 6.2 mmHg, p = 8.7×10- 6 in GENRES), a missense 
mutation of SPG7 gene, showed a suggestive replication in the Finn-Home study (n = 773, β = 2.4 
mmHg, p = 0.03). The effect was in the same direction in DYNAMIC, but the association was not 
significant (β = 2.2 mmHg, p = 0.4); however, in DILGOM the effect was in the opposite direction 
(β = -3.5 mmHg, p = 0.05). Meta-analysis of all four cohorts did not yield more significant p values 
(Supplementary Table 3). Sex × SNP interaction was significant only for rs4454147 in the Finn-
Home study, and the p value for the association of systolic WCE with this SNP was stronger in men 
(β = -1.6 mmHg, p= 0.07) than in men and women combined (β = -0.2 mmHg, p = 0.8) (Table 3). 
Genome-wide association study of diastolic white-coat effect 
The Q-Q plot from the discovery GWAS of diastolic WCE showed little evidence of genomic 
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inflation, suggesting that some of the associations may be significant (Supplementary Figure 2B). 
The Manhattan plot (Figure 1B) shows seven loci with p < 1×10-5, but no genome-wide significant 
SNPs were identified. The results of the discovery GWAS are summarized in in Table 4 and 
Supplementary Figure 4A-G. Like for systolic WCE, we also tested if the top diastolic WCE 
associations derived from the placebo periods were similar when WCE data during the four 
different drug periods were analyzed. As shown in the Supplementary Table 2, all the associations 
were consistently in the same direction and mostly statistically significant. 
In the replication analysis, no SNP reached the Bonferroni-corrected p value (0.003). 
However, rs10033652, an intronic SNP in RASGEF1B showed suggestive replication in DILGOM 
(β = 1.8 mmHg, p = 0.04) (Table 4). In the meta-analysis of all four cohorts no SNP reached 
genome-wide significance (Supplementary Table 3). Two SNPs (rs2650673 and rs11062980) had p 
values < 0.10 for sex × SNP interaction in at least one of the replication cohorts (Table 5). When 
analyzed separately, men showed stronger association for rs11062980 with diastolic WCE in 
DILGOM (β = 1.9 mmHg, p = 0.07) than men and women combined (β = -0.6 mmHg, p = 0.5). 
Candidate variants from a previous genome-wide association study of white-coat effect 
We conducted a replication analysis for the associations found in a previous GWAS of WCE [11]. 
No SNP reached the Bonferroni-corrected p value < 0.003 (Supplementary Table 4). Lowest p 
values were 0.03 for rs314668 (with different direction of effect) and 0.06 for rs7717374 with the 
same direction of effect, both for diastolic WCE. 
Discussion 
The present study was aimed at identifying genetic loci associated with WCE, i.e. the magnitude of 
the BP response to a clinic visit, using a systematic GWAS approach (discovery phase, replication 
studies and meta-analysis). Altogether, our study involved 1343 Finnish subjects, indicating the 
largest sample to study genetic associations of this trait thus far. We did not identify genome-wide 
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significant SNPs for either systolic or diastolic WCE, but 11 loci were identified at suggestive p 
value < 1 × 10-5, four for systolic WCE and seven for diastolic WCE. In the replication analysis, 
some support was obtained for two of these loci, rs2292954 in SPG7 and rs10033652 in 
RASGEF1B. In addition, two other SNPs (rs4454147 and rs11062980) with previous nominal 
associations with BP traits [31,34], showed stronger association with WCE in men than in men and 
women combined, pointing to a possible sex-specific effect. Lastly, cross-trait analysis revealed that 
four out of the 11 WCE loci identified in the hypertensive GENRES cohort have been previously 
nominally associated with neuroticism-related traits in at least two large publicly available GWASs 
of these phenotypes [31–33]. 
The most interesting finding from this study is the association of rs2292954 in SPG7 with 
larger systolic WCE as it has previously been associated with increased risk for coronary artery 
disease (p = 2.3 × 10-5) in the large CARDIoGRAM GWAS study [39]. It was also nominally 
associated with SBP (p = 0.01) and pulse rate (p = 0.02) in the recent UK Biobank GWAS by Neale 
lab [31], supporting its role in BP regulation. rs2292954 is a missense variant in the SPG7 gene 
causing the substitution of alanine for threonine, which is predicted to be tolerated by SIFT and 
benign by Polyphen (Supplementary Table 5). SPG7 codes for paraplegin, a subunit of 
mitochondrial mAAA protease, which is a pleiotropic enzyme regulating many mitochondrial 
functions [40]. As shown in the local Manhattan plot (Supplementary Figure 3B), this locus 
contains multiple linked SNPs (r2 > 0.8) with low p values, such as rs12960 (for the effect allele A: 
systolic WCE β = 6.1 mmHg, p = 4.0 × 10-6, r2 =0.98 with rs2292954 in GENRES). rs12960 is 
likewise a missense variant of SPG7, causing an amino acid change from arginine 688 to glutamine 
which is predicted by Polyphen to be probably damaging. The functional characterization of 
rs12960 suggests that this allele is a gain-of-function variant of SPG7 causing an increased activity 
of SPG7-containing mAAA proteases and resulting in increased reactive oxygen production in the 
mitochondria [41]. eQTL analysis of GTEx database [29,30] identified both rs2292950 and rs12960 
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as cis-acting eQTLs for SPG7, but also for nearby RPL13 (ribosomal protein L13) (Supplementary 
Table 5). 
We also observed association of rs10033652 with a larger diastolic WCE. We did not find 
any evidence that this intronic SNP of RASGEF1B or any other SNP in LD (Supplementary Figure 
4E) could be functional. RASGEF1B codes for a guanine-nucleotide exchange factor (GEF). Its 
expression in macrophages is stimulated by contact with bacterial lipopolysaccharides and it 
controls diverse Ras-protein-mediated signaling networks [42]. A recent study found that 
RasGEF1B circular RNA controls the expression of ICAM-1, an important adhesion molecule 
expressed in the endothelium, which attracts white blood cells to the vessel wall [43]. 
As the GENRES study consisted of only men, we investigated possible sex × SNP 
interaction in the replication cohorts. For two SNPs, rs4454147 and rs11062980, sex seemed to 
interact with the effect of the SNP on WCE. We observed a stronger association of rs4454147 with 
systolic WCE in men than in men and women combined. This intergenic SNP does not seem to be 
functional (Supplementary Table 5), but it has been nominally associated with BP levels previously 
in the ICBP GWAS (p = 0.02 for SBP and p = 0.03 for DBP) [34] and UK Biobank GWAS by 
Neale lab (p = 0.001 for SBP and p = 0.06 for DBP) [31] (Supplementary Table 6). Interestingly, 
Phenoscanner [35,36] query revealed that the associations of this SNP and obesity-related traits 
were also stronger in men than in women in the GIANT study [44] suggesting a possible sex-
specific effect. Likewise, rs11062980 had a stronger association with diastolic WCE in men in 
DILGOM compared to men and women combined. This intergenic SNP was a weak eQTL for a 
nearby lincRNA gene RP11-320N7.2 and pseudogene HSPA8P5 in GTEx database [29,30]. It has 
previously been nominally associated with DBP in UK Biobank GWAS by Neale lab (p = 0.03) 
[31] and notably also with nervous feelings (p = 0.03 in UK Biobank GWAS by Neale lab) [31] and 
neuroticism (p = 0.006 in the SSGAC GWAS) [33] (Supplementary Table 7). Possible sex-
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dependent genetic associations, although rarely investigated in BP genetics, would not be 
unexpected, as sex differences in BP regulation are well known [16]. 
We also sought to replicate the findings from a previous GWAS of WCE in the Japanese 
HOMED-BP study [11]. None of the associations replicated at the stringent Bonferroni-corrected p 
value limit <0.003. The best p values were 0.03 for rs314668 (closest gene ACTBL2) with different 
direction of effect and 0.06 for rs7717347 (strong eQTL for STRN4 expression in the GTEx 
database [29,30]) with same direction of effect. In addition, both WCE associated SNPs were also 
nominally associated with BP readings and neuroticism-related traits in the UK Biobank GWAS by 
Neale lab [31] (Supplementary Table 7). 
Psychological mechanisms related to anxiety are thought to influence WCE [3,45]. There is 
also some evidence that personality traits are associated with white-coat hypertension [46]. 
However, these associations were significant only in a subgroup that perceived themselves as 
hypertensive [45,46]. Thus, the association of anxious personality to WCE might depend on the 
self-experienced hypertension status of the patient. As all GENRES subjects were hypertensive, we 
queried three large publicly available GWASs of psychological traits (GPC, SSGAC, UK Biobank 
GWAS) [31–33] for association of the top WCE SNPs from GENRES GWAS with neuroticism and 
related psychological traits. Four out of eleven WCE loci, including rs9614176, rs7606893, 
rs2650673 and rs11062980 showed nominal association with neuroticism-related traits in at least 
two of the large GWASs queried (Supplementary Tables 6 and 7). Further studies on these loci 
could elucidate the mechanisms of cardiovascular response to stress in hypertensive patients. 
The present study has several limitations. The very specific phenotype under study 
necessarily limited possibilities to collect extensive patient materials, and accordingly the sample 
size is an obvious limitation of our study. On the other hand, the main strength of our study is the 
use of repeated measurements of WCE both in the discovery cohort (GENRES) and in the largest 
replication cohort (Finn-Home). Secondly, the discovery cohort (GENRES) consisted of men only, 
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whereas all three replication cohorts included both men and women; indeed, sex has been shown to 
associate with WCE [9]. On the other hand, this enabled us to study possible sex-dependent 
associations. Third, while GENRES and one of the replication samples (DYNAMIC) were 
dominated by hypertensive individuals, the other two replication cohorts (Finn-Home and 
DILGOM) were derived from population surveys. This may have caused a selection bias in 
GENRES. In addition, in GENRES, DYNAMIC and DILGOM the WCE was defined as the 
difference between OBP and daytime ABP, whereas in Finn-Home the WCE was defined as the 
difference between OBP and home BP. 
Conclusions 
We identified two novel candidate genes for white-coat effect in human hypertension. It is of note 
that some of the functions of these two genes are related to cardiovascular pathophysiology, 
mitochondrial function and inflammation. We also found some evidence for sex-dependent genetic 
associations with white-coat effect. Cross-trait association analysis gave some support for the 
hypothesis that the hypertensive white-coat effect could be associated with neuroticism-related 
personality traits. Additional studies from other populations, however, are required to validate our 
data. 
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Figure captions 
Figure 1. Manhattan plots of the association p values from the discovery genome-wide  association 
study in GENRES. (A) systolic white-coat effect (B) diastolic white-coat effect. The y-axis shows 
the -log10(p values) of each genotyped SNP and the x-axis shows their chromosomal position. The 
horizontal lines correspond to genome wide (5 × 10-8) and suggestive (1 × 10-5) p value thresholds. 
SNPs above the suggestive threshold are annotated. Abbreviations: SNP, single nucleotide 
polymorphism. 
SPG7MROH2A
A
B
PDCD6IP RASGEF1B
HLA PARP11 CDH8
FAXC
EFCAB6
Systolic white-coat effect
Diastolic white-coat effect
PARK2
VLDLR
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TABLE 1 Clinical characteristics of the discovery cohort (GENRES) and replication cohorts 
(DYNAMIC, Finn-Home and DILGOM). 
Parameter GENRES DYNAMIC Finn-Home DILGOM 
     
n 206 182 773 182 
Age (years) 50.8 ± 6.3 47.5 ± 11.7 55.6 ± 7.9 56.3 ± 11.3 
Men 100 % 60 %  48 % 47 %  
Body Mass Index (kgm-2) 26.5 ± 2.7 27.0 ± 4.1 27.3 ± 3.9 26.6 ± 4.4 
Antihypertensive use - - 21 % 29 % 
Smoking 16 % 15 % 22 % 8 % 
     
Blood pressure levels     
Office measurement     
   SBP (mmHg) 152 ± 13 145 ± 18 137 ± 19 129 ± 18 
   DBP (mmHg) 100 ± 7 92 ± 11 84 ± 8 79 ± 10 
Ambulatory measurement     
   Daytime SBP (mmHg) 144 ± 10 140 ± 13 - 128 ± 12 
   Daytime DBP (mmHg) 99 ± 6 88 ± 8 - 78 ± 8 
Home measurement     
   SBP (mmHg) - - 129 ± 17 - 
   DBP (mmHg) - - 81 ± 9 - 
     
Systolic WCE (mmHg) 7.5 ± 9.5 5.5 ± 14.6 8.0 ± 14.3 1.2 ± 13.9 
Diastolic WCE (mmHg) 0.3 ± 5.6 4.0 ± 8.6 3.6 ± 7.5 0.3 ± 8.5 
Values are presented as mean ± standard deviation.  
Abbreviations: SBP, systolic white-coat effect; DBP, diastolic white-coat effect; WCE,  
white-coat effect. 
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TABLE 2 Top SNPs associated with systolic white-coat effect in GENRES and replication in DYNAMIC, Finn-Home and DILGOM 1 
 GENRES 
(n = 206) 
 DYNAMIC 
(n =182) 
 Finn-Home 
(n = 773) 
 DILGOM 
(n = 182)  
Locus rsID 
Chr:Pos 
(build 37) 
Gene EA EAF β SE p  
 
β p 
 
β p 
 
β p 
1 rs9614176 22:43922499 EFCAB6 A 0.14 5.4 1.1 8.7×10-7  -1.7 (0.5)  -0.8 (0.4)  -1.1 (0.5) 
2 rs2292954 16:89613123 SPG7 G 0.10 6.2 1.3 2.3×10-6  2.2 0.4  2.4 0.03*  -3.5 (0.05) 
3 rs4454147 6:99575874 FAXC G 0.48 -3.7 0.8 2.9×10-6  0.1 (1.0)  -0.2 0.8  1.0 (0.5) 
4 rs7606893 2:234732816 MROH2A A 0.49 3.6 0.8 3.0×10-6  -0.3 (0.9)  -0.5 (0.5)  -0.9 (0.5) 
SNPs with p < 1×10-5 in the discovery GWAS in GENRES are shown in the order of significance.  2 
The effect (β) of each SNP on white-coat effect is presented as mmHg.   3 
* indicates suggestive replication with same direction of effect. 4 
p values are presented in parentheses if the direction of effect is different from the discovery GWAS. 5 
Abbreviations: SNP, single nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; EAF, effect allele frequency, SE, 6 
standard error.  7 
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TABLE 3 Replication analysis of top SNPs associated with systolic white-coat effect in GENRES in men only. 8 
GENRES 
(n = 206) 
 
 
DYNAMIC 
(n = 109) 
 Finn Home 
(n = 367) 
 DILGOM 
(n = 85) 
Locus rsID EA 
      WCE  
p(sex×SNP) 
WCE  
p(sex×SNP) 
WCE  
p(sex×SNP) 
WCE 
β p  β p  β p  β p 
1 rs9614176 A 5.4 8.7×10-7  0.8 - -  0.3 - -  0.6 - - 
2 rs2292954 G 6.2 2.3×10-6  0.7 - -  0.2 - -  1.0 - - 
3 rs4454147 G -3.7 2.9×10-6  0.3 1.2 (0.5)  0.04* -1.6 0.07  0.2 3.0 (0.12) 
4 rs7606893 A 3.6 3.0×10-6  0.2 - -  0.2 - -  0.8 - - 
Separate replication analysis was conducted in men only if sex×SNP interaction p value was < 0.10 in any of the replication cohorts.  9 
The effect (β) of each SNP on white-coat effect is presented as mmHg.  10 
* indicates significant sex×SNP interaction. 11 
p values are presented in parentheses if the direction of effect is different from the discovery GWAS. 12 
Abbreviations: SNP, single nucleotide polymorphism; EA, effect allele; WCE, white-coat effect  13 
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TABLE 4 Top SNPs associated with diastolic white-coat effect in GENRES and replication in DYNAMIC, Finn-Home and DILGOM 14 
 
GENRES 
(n = 206) 
 
DYNAMIC 
(n =182) 
 
Finn Home 
(n = 773) 
 
DILGOM 
(n = 182) 
Locus rsID Chr:Pos Gene EA EAF β SE p  β p  β p  β p 
1 rs10965522 9:2301692 VLDLR A 0.24 2.8 0.6 1.7×10-6  0.4 0.7  0.0 1.0  -0.5 (0.6) 
2 rs2650673 16:61120981 CDH8 A 0.44 2.2 0.5 3.6×10-6  0.1 0.9  0.1 0.9  -0.2 (0.8) 
3 rs11062980 12:4150135 PARP11 A 0.44 -2.3 0.5 4.4×10-6  1.8 (0.06)  0.2 (0.6)  -0.6 0.5 
4 rs2064479 6:33072240 HLA-DPB1 A 0.28 2.4 0.5 4.5×10-6  0.1 0.9  0.1 0.8  -0.3 (0.8) 
5 rs10033652 4:82493067 RASGEF1B A 0.49 2.2 0.5 4.9×10-6  0.4 0.7  -0.3 (0.4)  1.8 0.04* 
6 rs2053425 3:34241686 PDCD6IP A 0.25 2.3 0.5 7.7×10-6  0.4 0.8  -0.7 (0.11)  -1.4 (0.2) 
7 rs6921226 6:162128543 PARK2 G 0.41 -2.2 0.5 9.9×10-6  1.0 (0.3)  0.3 (0.4)  -0.4 0.7 
SNPs with p < 1×10-5 in the discovery GWAS in GENRES are shown in the order of significance.  15 
The effect (β) of each SNP on white-coat effect is presented as mmHg.   16 
* indicates suggestive replication with same direction of effect. 17 
p values are presented in parentheses if the direction of effect is different from the discovery GWAS. 18 
SNP, single nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; EAF, effect allele frequency, SE, standard error.  19 
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TABLE 5 Replication analysis of top SNPs associated with diastolic white-coat effect in GENRES in men only. 20 
GENRES 
(n = 206) 
 DYNAMIC 
(n = 109) 
 Finn Home 
(n = 367) 
 DILGOM 
(n = 85) 
Locus rsID EA 
      WCE  
P(sex×SNP) 
WCE  
P(sex×SNP) 
WCE  
P(sex×SNP) 
WCE 
β P  β P  β P  β P 
1 rs10965522 A 2.8 1.7×10-6 
 
0.2 - -  0.8 - -  0.5 - - 
2 rs2650673 A 2.2 3.6×10-6 
 
0.6 -0.5 (0.7)  0.7 -0.1 (0.9)  0.097* 1.8 0.2 
3 rs11062980 A -2.3 4.4×10-6 
 
0.06* 0.8 (0.5)  0.3 -0.3 0.6  0.12 -1.9 0.07 
4 rs2064479 A 2.4 4.5×10-6 
 
0.6 - -  0.8 - -  0.4 - - 
5 rs10033652 A 2.2 4.9×10-6 
 
0.2 - -  0.9 - -  0.9 - - 
6 rs2053425 A 2.3 7.7×10-6 
 
0.9 - -  0.2 - -  0.3 - - 
7 rs6921226 G -2.2 9.9×10-6 
 
0.6 - -  0.9 - -  0.6 - - 
Separate replication analysis was conducted in men only if sex×SNP interaction p value was < 0.10 in any of the replication cohorts.  21 
The effect (β) of each SNP on white-coat effect is presented as mmHg.  22 
* indicates significant sex×SNP interaction (p < 0.10). 23 
p values are presented in parentheses if the direction of effect is different from the discovery GWAS. 24 
Abbreviations: SNP, single nucleotide polymorphism; EA, effect allele; WCE, white-coat effect. 25 
Systolic WCE Diastolic WCE
β / p β / p
Ambulatory daytime SBP -0.2 / 0.002 -
Ambulatory daytime DBP - -0.2/7.8×10-4
Age normalized 4.1 / 9.9×10-11 1.8 / 7.2×10-7
Body mass index kgm-2 0.1 / 0.13 0.4 / 0.001
Smoking (1=no, 2=yes) -4.177 / 0.01 -1.3 / 0.189
Previous antihypertensive medication (1=no, 2=yes) ns ns
Waist-hip ratio ns ns
Serum Creatinine ns ns
dU-Na ns ns
r2 of the model 0,25 0,23
Adjusted r2 of the model 0,24 0,22
Supplementary Table 1: Covariates used to generate regression residuals for white-coat effect in GENRES
Lifestyle factor
A covariate was included in the models if association p value was < 0.10 for either systolic or diastolic WCE. 
Abbreviations: WCE, white-coat effect; SBP, systolic blood pressure; DBP, diastolic blood pressure
Supplementary Figure 1. The GENRES Study design. The timings of the placebo OBP and ABP measurements used for the discovery GWAS
are marked in the figure with black arrows and blue boxes. Abbreviations: OBP, office blood pressure; ABP, ambulatory blood pressure; ECG,
electrocardiography.
Supplementary Figure 2. Quantile-quantile plots of the association results.
This figure shows the quantile-quantile plots created in R for two-sided P values of the genome-wide
association analysis on (A) systolic white coat effect and (B) diastolic white coat effect. The x-axis shows
the expected distribution of ¬ log10(p values) and the y-axis shows the observed  log10(p values).
A
B
Supplementary Figure 3. LocusZoom plots of the top loci for systolic white coat effect in GENRES.
This figure shows the regional Manhattan plots created with LocusZoom for the best loci for systolic WCE
in the discovery cohort (GENRES). The y-axis shows the -log10(p value) of each genotyped SNP and the x-
axis shows their chromosomal position. Blue line depicts the recombination rate from HAPMAP(EU)
population. The SNPs are coloured to reflect pairwise LD (r2) with the most significantly associated SNP in
GENRES. Genes mapping to each locus are shown in the lower panel.
A rs9614176 B rs2292954
C rs4454147 D rs7606893
Supplementary Figure 4. LocusZoom plots of the top loci for diastolic white coat effect.
This figure shows the regional Manhattan plots created with LocusZoom for the best loci for systolic WCE
in the discovery cohort (GENRES). The y-axis shows the -log10(p value) of each genotyped SNP and the x-
axis shows their chromosomal position. Blue line depicts the recombination rate from HAPMAP(EU)
population. The SNPs are coloured to reflect pairwise LD (r2) with the most significantly associated SNP in
GENRES. Genes mapping to each locus are shown in the lower panel.
A rs10965522 B rs2650573
C rs11062980 D rs2064479
E rs10033625 F rs2053425
G rs6921226
